Nvidia CEO Jensen Huang Says Demand for Its Chips Is ‘Insane' Ivar AI

The Times of India

US stocks: SpaceX to make historic listing on Nasdaq on Friday that could make Elon Musk a trillionaire

BusinessLine

SpaceX IPO pushes Elon Musk’s net worth past $1 trillion

Crypto Briefing

US Army helicopter shot down by Iran near Strait of Hormuz, Trump confirms

POLITICO.eu

US launches a second straight day of airstrikes in Iran

Www.abc.es

¿Podrá el mercado bursátil digerir a Anthropic, SpaceX y OpenAI?

Yahoo Entertainment

美國會遏阻伊朗無人機技術中東衝突升級油價飆漲

Crypto Briefing

IRGC Navy strikes two oil tankers in Strait of Hormuz, escalating crisis at world’s most critical oil chokepoint

Digitimes

AI chip race lifts semiconductor equipment sales to record US$36.55bn

Yahoo Entertainment

《大賣空》本尊示警！AI三巨頭IPO募資規模超越網路泡沫

GlobeNewswire

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

CNA

Oppenheimer launches Wall Street's first coverage of SpaceX with bullish outlook

Ig.com.br

EUA iniciam ataques contra o Irã após queda de helicóptero

CBS News

U.S. launches more strikes on Iranian targets after Trump promises to hit Iran "hard"

Crypto Briefing

SpaceX achieves largest IPO in history, nearing trillionaire status for Elon Musk

Www.abc.es

EE.UU. ataca Irán «en legítima defensa» por el «derribo» de un helicóptero en Ormuz

TechRadar

This Microsoft Defender zero-day could give hackers unprecedented access to your system

Crypto Briefing

US fires 49 Tomahawk missiles at Iran in major escalation

Al Jazeera English

US bombs Iran after Trump threat, Tehran closes Hormuz Strait to all ships

The Daily Caller

China Pours More Fuel On The AI Arms Race Fire

Le HuffPost

Hegseth et Trump avaient prévenu, les États-Unis ont lancé de nouvelles frappes contre l’Iran

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire